Pictured: Biotech Resources CEO Peter Jordan and his research team with MTPConnect Chair Sue MacLeman and MTAA CEO Ian Burgess in April 2018 at the launch of BioMedTech Horizons in Melbourne.
Biotech Resources (BTR) is working to develop the world’s first rapid diagnostic test ‘Aimalux’ for the direct detection of the bacteria and fungi that cause sepsis from whole blood. The technology and platform has been developed by the Monash University Centre for Biospectroscopy in Melbourne Australia.
Sepsis is a life-threatening disease that results in the deaths of over 6 million people every year around the world, and more than 5,000 Australians. It is time critical medical emergency. Every hour without treatment increases a patient's chance of dying by 7.6%. And yet there is no definitive test for sepsis with more than 30% of cases going misdiagnosed. If the symptoms of Sepsis are missed and treatment is not administered, then this can result in patient death. This also means that many patients are treated unnecessarily as a precaution, which has its own detrimental consequences as well as adding to the rise of antibiotic resistance super bugs.
Aimalux aims to provide a diagnostic result within 35 minutes, to revolutionise the way sepsis is currently diagnosed, reduce healthcare costs, and save lives.
Visit Biotech Resources for more information.
LinkedIn: Biotech Resources (Aust) Pty. Ltd.
|Consortium Lead:||Biotech Resources (AUST) Pty Ltd|
|Consortium Partners:||Monash University Centre for Biospectroscopy, The Alfred Hospital, Monash Health, Hydrix|
|Contact:||Peter Jordan, CEO of Biotech Resources - email@example.com|